Upregulation of CRM1 in cancer cells results in the cytoplasmic accumulation of multiple tumor suppressor proteins, such as p53, p21, p27, APC, FOXO and BRCA1, and therefore disables their nuclear functions in preventing tumor initiation, growth and progression [64–69], suggesting that CRM1 is an attractive anti-cancer drug target. Here, TP53 is linked to neoplasm.